Multimodal Imaging Gd-Nanoparticles Functionalized with Pittsburgh Compound B Or a Nanobody for Amyloid Plaques Targeting

Total Page:16

File Type:pdf, Size:1020Kb

Multimodal Imaging Gd-Nanoparticles Functionalized with Pittsburgh Compound B Or a Nanobody for Amyloid Plaques Targeting Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh compound B or a nanobody for amyloid plaques targeting. Jonathan Pansieri, Marie Plissonneau, Nathalie Stransky-Heilkron, Mireille Dumoulin, Laurence Heinrich-Balard, Pascaline Rivory, Jean-François Morfin, Éva Tóth, Saraiva Maria Joao, Eric Allémann, et al. To cite this version: Jonathan Pansieri, Marie Plissonneau, Nathalie Stransky-Heilkron, Mireille Dumoulin, Laurence Heinrich-Balard, et al.. Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh com- pound B or a nanobody for amyloid plaques targeting.. Nanomedicine, Future Medicine, 2017, 12 (14), pp.1675-1687. 10.2217/nnm-2017-0079. hal-01561318 HAL Id: hal-01561318 https://hal.archives-ouvertes.fr/hal-01561318 Submitted on 5 Feb 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Research Article For reprint orders, please contact: [email protected] 12 Research Article 2017/06/30 Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh compound B or a nanobody for amyloid plaques targeting Jonathan Pansieri‡,1, Marie Nanomedicine (Lond.) Plissonneau‡,2,3, Nathalie Aim: Gadolinium-based nanoparticles were functionalized with either the Pittsburgh Stransky-Heilkron4, Mireille compound B or a nanobody (B10AP) in order to create multimodal tools for an early Dumoulin5, Laurence diagnosis of amyloidoses. Materials & methods: The ability of the functionalized Heinrich-Balard6, Pascaline nanoparticles to target amyloid fibrils made of β-amyloid peptide, amylin or Val30Met- Rivory6, Jean-François mutated transthyretin formed in vitro or from pathological tissues was investigated by Morfin7, Eva Toth7, Maria a range of spectroscopic and biophysics techniques including fluorescence microscopy. Joao Saraiva8, Eric Allémann4, Results: Nanoparticles functionalized by both probes efficiently interacted with the Olivier Tillement3, Vincent 1 ‡,3 three types of amyloid fibrils, with K values in 10 micromolar and 10 nanomolar Forge , François Lux & D ,‡,1 range for, respectively, Pittsburgh compound B and B10AP nanoparticles. Moreover, Christel Marquette* 1Laboratoire de Chimie et Biologie des they allowed the detection of amyloid deposits on pathological tissues. Conclusion: Métaux, Université Grenoble Alpes, CEA Such functionalized nanoparticles could represent promising flexible and multimodal Life Sciences Division, CNRS, 17 rue des imaging tools for the early diagnostic of amyloid diseases, in other words, Alzheimer’s Martyrs, 38054 Grenoble Cedex 9, France disease, Type 2 diabetes mellitus and the familial amyloidotic polyneuropathy. 2Nano-H S.A.S, 38070 Saint Quentin Fallavier, France 3Institut Lumière Matière, University First draft submitted: 10 March 2017; Accepted for publication: 24 May 2017; Published of Lyon, University of Claude Bernard online: 21 June 2017 Lyon 1, CNRS, F-69622, Lyon, France 4School of Pharmaceutical Sciences, Keywords: amyloid imaging • amyloidoses • gadolinium-based nanoparticles • nanobody University of Geneva, University of • PIB Lausanne Pharmaceutical technology, Quai Ernest-Ansermet 30, 1211 Geneva, Switzerland Amyloidoses are a set of human diseases in and especially the early diagnosis, remains 5Laboratory of Enzymology & Protein which a normally soluble peptide or protein therefore a great challenge and often requires Folding, Centre for Protein Engineering, InBioS, University of Liege Sart Tilman, aggregates into insoluble and highly orga- several invasive examinations [6,7]. 4000 Liege, Belgium nized aggregates referred to as amyloid fibres. Therefore, there is a need to develop sen- 6 14 University of Lyon, University of These aggregates are rich in cross-β-sheet sitive and minimally invasive tools to detect Claude Bernard Lyon 1, ISPB Faculté de structures [1,2]. So far, 36 proteins are associ- amyloid deposits, in order not only to estab- Pharmacie, MATEIS UMR CNRS 5510, 69373 Lyon, France. ated with either local (e.g., Type 2 diabetes lish the diagnosis of amyloidosis [8] but also 7 mellitus [T2DM] and Alzheimer’s disease allow to follow-up the efficiency of treatment Centre de Biophysique Moléculaire, 2017 CNRS, UPR 4301, Université d’Orléans, Rue [AD]) or systemic (e.g., familial polyneurop- by monitoring the evolution of the amyloid Charles Sadron, 45071 Orléans, France athy and myeloma) amyloid depositions [3]. load [9]. Nowadays, a number of imaging 8Instituto de Inovação e Investigação em These diseases inflict enormous psycho- techniques can be used for these purposes; Saúde (I3S), University of Porto, Portugal; sociological and economic burdens. For they include PET and MRI to detect the Molecular Neurobiology Group, IBMC example, AD and T2DM affect, respectively, deposition of Aβ amyloid in the brain of AD – Institute for Molecular & Cell Biology, University of Porto, 4150–180 Porto, approximately 44 and 415 million people patients [10,11], scintigraphy to detect V30M- Portugal worldwide [4,5]. TTR fibrils involved in cardiac amyloido- *Author for correspondence: Symptoms of amyloidoses, especially in sis [12], autoradiography to target islet amyloid [email protected] ‡Authors contributed equally the cases of systemic amyloidoses, can be polypeptide (IAPP) fibrils in T2DM [13], etc. very subtle and vary widely from person to However, each of these techniques presents person and also depend on which organs some limitations. For example, while MRI are affected. The diagnosis of amyloidosis allows obtaining an outstanding spatial reso- part of 10.2217/nnm-2017-0079 © 2017 Future Medicine Ltd Nanomedicine (Lond.) (Epub ahead of print) ISSN 1743-5889 Research Article Pansieri, Plissonneau, Stransky-Heilkron et al. lution it strongly lacks sensitivity (1–0.01 millimolar fragments displaying a high specificity and affinity range) [14] . On the other hand, PET offers an excellent for the targeted fibrils [29]. For example, an enhanced sensitivity (10–1 pM range) but has a low spatial reso- amyloid-β plaques detection by MRI was observed lution [15] . In order to overcome these limitations, the within AD transgenic mouse using SuperParamagnetic development of probes allowing multimodal imaging Iron Oxide Nanoparticles functionalized with an anti- approaches (i.e., combination of PET and MRI) will AβPP antibody [30]. In this work, we have chosen to represent a breakthrough in the diagnosis of amyloido- functionalize AGuIX with the B10AP which is a chi- ses [16,17]. In this context, nanoparticles have emerged meric protein made of B10, a nanobody (i.e., the vari- in the past decades as a very promising tool to enhance able domain of heavy-chain antibodies) and Escherichia the contrast and the sensitivity of these different imag- coli alkaline phosphatase (AP). B10 has been selected ing techniques. by phage display from a synthetic library of nanobod- In this work, we have functionalized gadolinium ies using Aβ(1–40) fibrils as bait [31] . It also recognizes (Gd) based multimodal nanoparticles (NPs), so called amyloid fibrils of several proteins (madein vitro and on AGuIX with specific probes for the diagnosis of amy- tissues) including insulin, glucagon, β2-microglobulin, loidoses. AGuIX are made of a polysiloxane network serum amyloid A protein and immunoglobulin light 3+ surrounded by several DOTAGA (Gd ) chelates [18,19]. chain (AL) [32]. AP forms homodimers and therefore AGuIX NPs have a diameter smaller than 5 nm and B10AP exhibits two copies of B10 within one molecule have been already efficiently used for MRI and radio- of the chimera; such a bivalent construct exhibits a sensitization [20]. Free ligands are available at the sur- higher overall affinity for Aβ(1–42) amyloid fibrils with face of AGuIX and can be used to chelate radioisotopes a lower dissociation constant (KD: 7 nM and 475 nM 68 3+ 111 3+ (e.g., Ga or In ), in order to perform PET or for B10AP and B10, respectively) [32]. Moreover, the single-photon emission computed tomography imag- phosphatase activity of AP allows an easy and straight- ing [14,21] . Moreover, the covalent grafting of a near forward monitoring of B10AP binding to the amyloid infrared dye, such as cyanine5.5 (Cy5.5), is also achiev- fibrils. able for optical imaging [22]. Finally, we have recently In this work, we have used PIB and B10AP as graft- shown that AGuIX can be functionalized with specific ing ligands on AGuIX NPs, in order to perform active Aβ peptides to selectively target and image Aβ-amyloid targeting on Aβ(1–42) fibrils which deposit in the brain fibrils [23]. However, while the results obtained clearly of AD patients; IAPP fibrils that accumulate in Lang- demonstrate that these functionalized NPs constitute erhans Islet of patients affected with T2DM; and a valuable multimodal imaging tool to selectively tar- V30M-TTR fibrils associated with familial amyloidotic get Aβ fibrils, they displayed a low affinity (100 μM polyneuropathy (FAP). range) for their target. Therefore, the aim of the present work is to functionalize AGuIX with molecules having Methods higher affinity for amyloid
Recommended publications
  • Thioflavin Derivatives for Use in the Diagnosis of Alzheimer's Disease
    (19) TZZ Z__T (11) EP 2 264 018 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 277/66 (2006.01) C07D 277/64 (2006.01) 11.02.2015 Bulletin 2015/07 A61K 49/00 (2006.01) A61K 31/428 (2006.01) A61K 51/04 (2006.01) A61P 25/28 (2006.01) (2006.01) (21) Application number: 10185669.8 G01N 33/534 (22) Date of filing: 24.08.2001 (54) Thioflavin derivatives for use in the diagnosis of Alzheimer’s disease Thioflavinderivate zur Diagnose der Alzheimerschen Krankheit Dérivés de thioflavine pour le diagnostic de la maladie d’Alzheimer (84) Designated Contracting States: (72) Inventors: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU • Klunk, William, E. MC NL PT SE TR Pittsburgh, PA 15218 (US) Designated Extension States: • Mathis, Chester, A., JR. AL LT LV MK RO SI Pittsburgh, PA 15238 (US) • Wang, Yanming (30) Priority: 24.08.2000 US 227601 P Imperial, PA 15126 (US) (43) Date of publication of application: (74) Representative: Plougmann & Vingtoft A/S 22.12.2010 Bulletin 2010/51 Rued Langgaards Vej 8 2300 Copenhagen S (DK) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (56) References cited: 01966165.1 / 1 334 091 WO-A-97/26919 WO-A1-01/14354 (73) Proprietor: University of Pittsburgh - Of the Commonwealth System of Higher Education Pittsburgh, PA 15260 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • In Vitrocharacterization of Pittsburgh Compound-B Binding to Lewy Bodies
    The Journal of Neuroscience, September 26, 2007 • 27(39):10365–10371 • 10365 Neurobiology of Disease In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies Michelle T. Fodero-Tavoletti,1,2,4 David P. Smith,1,4 Catriona A. McLean,5 Paul A. Adlard,4 Kevin J. Barnham,1,2,4 Lisa E. Foster,1 Laura Leone,1 Keyla Perez,1,2,4 Mikhalina Corte´s,4 Janetta G. Culvenor,1,3,4 Qiao-Xin Li,1,4 Katrina M. Laughton,1,4 Christopher C. Rowe,6 Colin L. Masters,1,4 Roberto Cappai,1,2,4 and Victor L. Villemagne1,4,6 1Department of Pathology, 2Bio21 Institute, and 3Centre for Neuroscience, The University of Melbourne, Melbourne, Victoria 3010, Australia, 4The Mental Health Research Institute of Victoria, Parkville, Victoria 3052, Australia, 5Department of Anatomical Pathology, Alfred Hospital, Prahran, Victoria 3181, Australia, and 6Centre for PET, Austin Hospital, Heidelberg, Victoria 3084, Australia Dementia with Lewy bodies (DLB) is pathologically characterized by the presence of ␣-synuclein-containing Lewy bodies within the neocortical, limbic, and paralimbic regions. Like Alzheimer’s disease (AD), A␤ plaques are also present in most DLB cases. The contri- bution of A␤ to the development of DLB is unclear. [ 11C]-Pittsburgh compound B ([ 11C]-PIB) is a thioflavin-T derivative that has allowed in vivo A␤ burden to be quantified using positron emission tomography (PET). [ 11C]-PIB PET studies have shown similar high cortical [ 11C]-PIB binding in AD and DLB subjects. To establish the potential binding of PIB to ␣-synuclein in DLB patients, we characterized the in vitro binding of PIB to recombinant human ␣-synuclein and DLB brain homogenates.
    [Show full text]
  • Vizamyl, INN-Flutemetamol (18F)
    26 June 2014 EMA/546752/2014 Committee for Medicinal Products for Human Use (CHMP) Vizamyl flutemetamol (18F) Procedure No. EMEA/H/C/002553 Marketing authorisation holder: GE HEALTHCARE LIMITED Assessment report for an initial marketing authorisation application Assessment report as adopted by the CHMP with all commercially confidential information deleted 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Manufacturers ...................................................................................................... 8 1.3. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion ................................................................................ 9 2.1. Introduction......................................................................................................... 9 2.2. Quality aspects .................................................................................................. 11 2.2.1. Introduction ...................................................................................................
    [Show full text]
  • Thioflavin-Positive Tau Aggregates Complicating Quantification
    www.nature.com/scientificreports OPEN Thiofavin‑positive tau aggregates complicating quantifcation of amyloid plaques in the brain of 5XFAD transgenic mouse model Jisu Shin, Sohui Park, HeeYang Lee & YoungSoo Kim* Transgenic mouse models recapitulating Alzheimer’s disease (AD) pathology are pivotal in molecular studies and drug evaluation. In transgenic models selectively expressing amyloid‑β (Aβ), thiofavin S (ThS), a fuorescent dye with β‑sheet binding properties, is widely employed to observe amyloid plaque accumulation. In this study, we investigated the possibility that a commonly used Aβ‑expressing AD model mouse, 5XFAD, generates ThS‑positive aggregates of β‑sheet structures in addition to Aβ fbrils. To test this hypothesis, brain sections of male and female 5XFAD mice were double‑stained with ThS and monoclonal antibodies against Aβ, tau, or α‑synuclein, all of which aggregates are detected by ThS. Our results revealed that, in addition to amyloid plaques, 5XFAD mice express ThS‑positive phospho‑tau (p‑tau) aggregates. Upon administration of a small molecule that exclusively disaggregates Aβ to 5XFAD mice for six weeks, we found that the reduction level of plaques was smaller in brain sections stained by ThS compared to an anti‑Aβ antibody. Our fndings implicate that the use of ThS complicates the quantifcation of amyloid plaques and the assessment of Aβ‑targeting drugs in 5XFAD mice. Alzheimer’s disease (AD) is defned by accumulation of amyloid-β (Aβ) plaques and neurofbrillary tau tangles in the brain, leading to neurodegeneration and cognitive dysfunction 1. Te need for deeper molecular under- standing underlying AD pathogenesis and the discovery of efective therapeutics has led to the development of transgenic mouse models mimicking Aβ and tau pathologies.
    [Show full text]
  • Characterizing Interactions of Thioflavin-T with Native Proteins
    Characterizing Interactions of Thioflavin-T with Native Proteins Especially Bovine Serum Albumin by Caleb Matthew Stratton April, 2017 Director of Thesis: Atta Ahmad (PhD) Major Department: Biology Abstract Thioflavin T is a fluorescent probe used to monitor formation of cross β-sheet rich amyloid fibrils. Involvement of the amyloid fibrils is implicated in more than 50 human diseases, such as Alzheimer’s, Parkinson’s and Prion’s. The proteins responsible for each of these diseases many as well as model proteins have been used to unravel the process involved in native protein to amyloid transformation, especially, for drug design but with little success thus far. Bovine serum albumin (BSA), predominantly α-helical in constitution, is one such protein that has been observed to transform to β-sheet rich amyloid. For our thesis project, we set on with these basic lines of evidence for ThT and BSA and devised a study outline. The study was divided into sub sections for better redressal compared to what was reported in literature viz., 1) Characterizing the steps involved in the transformation of BSA from native to amyloid state, 2) Develop methodology to gain information of as many steps as possible, 3) Identify the structural changes triggering BSA on pathway to fibrillation, 4) Computational comparison of the sites with chaperone binding sites and finally 5) if from point 4 we could observe chaperones interfering the aggregation process of BSA. During this thesis work, we observed an unexpected interaction of the reporter ThT molecule with the native BSA. We expanded this further and used a suite of standard proteins and found that ThT has the unlikely affinity to bind to some of the proteins, which are predominantly helical in nature.
    [Show full text]
  • Inhalable Thioflavin S for the Detection of Amyloid Beta Deposits
    molecules Article Inhalable Thioflavin S for the Detection of Amyloid Beta Deposits in the Retina Shawn M. Barton 1,2 , Eleanor To 3, Baxter P. Rogers 1,2,4,5 , Clayton Whitmore 1,2, Manjosh Uppal 3, Joanne A. Matsubara 3,* and Wellington Pham 1,2,4,6,7,8,9,10,* 1 Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN 37232, USA; [email protected] (S.M.B.); [email protected] (B.P.R.); [email protected] (C.W.) 2 Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, USA 3 Department of Ophthalmology and Visual Sciences, The University of British Columbia, Eye Care Center, Vancouver, BC V5Z 3N9, Canada; [email protected] (E.T.); [email protected] (M.U.) 4 Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA 5 Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN 37212, USA 6 Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37232, USA 7 Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA 8 Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN 37232, USA 9 Vanderbilt Institute of Nanoscale Science and Engineering, Vanderbilt University, Nashville, TN 37235, USA 10 Vanderbilt Memory and Alzheimer’s Center, Vanderbilt University Medical Center, Nashville, TN 37212, USA * Correspondence: [email protected] (J.A.M.); [email protected] (W.P.) Abstract: We present an integrated delivery technology herein employing the aerosolized method to repurpose thioflavin S for imaging amyloid beta (Abeta) deposits in the retina as a surrogate of Abeta in the brain for early detection of Alzheimer’s disease.
    [Show full text]
  • Extracellular Amyloid Deposits in Alzheimer's and Creutzfeldt
    International Journal of Molecular Sciences Review Extracellular Amyloid Deposits in Alzheimer’s and Creutzfeldt–Jakob Disease: Similar Behavior of Different Proteins? Nikol Jankovska 1,*, Tomas Olejar 1 and Radoslav Matej 1,2,3 1 Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University and Thomayer Hospital, 100 00 Prague, Czech Republic; [email protected] (T.O.); [email protected] (R.M.) 2 Department of Pathology, First Faculty of Medicine, Charles University, and General University Hospital, 100 00 Prague, Czech Republic 3 Department of Pathology, Third Faculty of Medicine, Charles University, and University Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic * Correspondence: [email protected]; Tel.: +42-026-108-3102 Abstract: Neurodegenerative diseases are characterized by the deposition of specific protein aggre- gates, both intracellularly and/or extracellularly, depending on the type of disease. The extracellular occurrence of tridimensional structures formed by amyloidogenic proteins defines Alzheimer’s disease, in which plaques are composed of amyloid β-protein, while in prionoses, the same term “amyloid” refers to the amyloid prion protein. In this review, we focused on providing a detailed di- dactic description and differentiation of diffuse, neuritic, and burnt-out plaques found in Alzheimer’s disease and kuru-like, florid, multicentric, and neuritic plaques in human transmissible spongiform encephalopathies, followed by a systematic classification of the morphological similarities and differ- ences between the extracellular amyloid deposits in these disorders. Both conditions are accompanied by the extracellular deposits that share certain signs, including neuritic degeneration, suggesting a particular role for amyloid protein toxicity. Keywords: Alzheimer’s disease; Creutzfeldt–Jakob disease; Gerstmann–Sträussler–Scheinker syn- drome; amyloid; senile plaques; PrP plaques; plaque subtypes Citation: Jankovska, N.; Olejar, T.; Matej, R.
    [Show full text]
  • Imaging Technology for Neurodegenerative Diseases Progress Toward Detection of Specific Pathologies
    NEUROLOGICAL REVIEW Imaging Technology for Neurodegenerative Diseases Progress Toward Detection of Specific Pathologies Chester A. Mathis, PhD; William E. Klunk, MD, PhD; Julie C. Price, PhD; Steven T. DeKosky, MD dvances in neuroimaging over the past 2 decades are products of breakthroughs in imaging technology, developments of more powerful computers and image- processing software, and expanding knowledge in basic and clinical neuroscience. In addition to the insights into normal brain structure and function that such methods Aprovide and the information that can be gained from disease-related changes in structure and func- tion, the promise of achieving diagnostic specificity through neuroimaging lies with the potential identification of pathognomonic proteins. Recent advances in imaging ␤-amyloid plaques, one of the hallmarks of Alzheimer disease, offer such a technological breakthrough and the possibility for more efficient assessment of antiamyloid interventions as well as specific noninvasive diagnos- tic capabilities. Arch Neurol. 2005;62:196-200 In the last several decades of the 20th cen- and other pathological disturbances. Tech- tury and the first several years of the 21st, niques for the rapid assessment of blood research and the clinical application of flow advanced functional imaging and the neuroimaging have proceeded at a dizzy- localization of brain activity or function. ing and accelerating rate. Structural im- Magnetic resonance spectroscopy contin- aging was initially limited to skull and ues to develop as another method for the spine radiographs and subsequently to in- noninvasive assessment of brain metabo- ference about what was happening in the lism in development, aging, and disease. brain by analyzing the patterns of arte- The development of positron emis- rial, capillary, and venous blood flow on sion tomography (PET) has followed a cerebral angiography.
    [Show full text]
  • Modeling Neurodegenerative Disorders in Drosophila Melanogaster
    International Journal of Molecular Sciences Review Modeling Neurodegenerative Disorders in Drosophila melanogaster Harris Bolus 1, Kassi Crocker 2,3, Grace Boekhoff-Falk 3,* and Stanislava Chtarbanova 1,* 1 Department of Biological Sciences, University of Alabama, Tuscaloosa, AL 35487, USA; [email protected] 2 Genetics Graduate Training Program, School of Medicine and Public Health, University of Wisconsin–Madison, Madison, WI 53705, USA; [email protected] 3 Department of Cell and Regenerative Biology, School of Medicine and Public Health, University of Wisconsin–Madison, Madison, WI 53705, USA * Correspondence: grace.boekhoff@wisc.edu (G.B.-F.); [email protected] (S.C.) Received: 18 March 2020; Accepted: 21 April 2020; Published: 26 April 2020 Abstract: Drosophila melanogaster provides a powerful genetic model system in which to investigate the molecular mechanisms underlying neurodegenerative diseases. In this review, we discuss recent progress in Drosophila modeling Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Ataxia Telangiectasia, and neurodegeneration related to mitochondrial dysfunction or traumatic brain injury. We close by discussing recent progress using Drosophila models of neural regeneration and how these are likely to provide critical insights into future treatments for neurodegenerative disorders. Keywords: Drosophila; neurodegeneration; neuroregeneration 1. Introduction: Drosophila as a Model System for Studies of Human Disease The common fruitfly Drosophila melanogaster has been used as a genetic model system for more than 100 years. Because Drosophila are inexpensive to maintain and reproduce rapidly, an enormous repertoire of genetic technologies has been created over the past century [1]. Drosophila possess extensive homology with humans at the genetic level making them a useful model for investigation of the cellular and molecular processes underlying development and disease [2].
    [Show full text]
  • Spectral Properties of Thioflavin T and Its Complexes with Amyloid Fibrils
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE Journal of Applied Spectroscopy, Vol. 70, No. 6, 2003 SPECTRAL PROPERTIES OF THIOFLAVIN T AND ITS COMPLEXES WITH AMYLOID FIBRILS ∗ E. S. Voropai,a M. P. Samtsov,a K. N. Kaplevskii,a A. A. Maskevich,b UDC 535.37 V. I. Stepuro,b O. I. Povarova,c I. M. Kuznetsova,c K. K. Turoverov,c A. L. Fink,d and V. N. Uverskiid,e Comparative analysis of the absorption and fluorescence spectra and fluorescence excitation spectra of thioflavin T (ThT) in various solvents and in the composition of amyloid fibrils has shown that ThT, when ex- cited in the region of the long-wavelength absorption band, fluoresces in the spectral region with a maximum at 478–484 nm. The appearance in aqueous and alcohol solutions of a fluorescence band with a maximum near 440 nm has been attributed to the presence in the composition of the ThT preparations of an impurity with an absorption band in the 340–350-nm range. The literature data showing that in glycerol ThT has a wide fluorescence spectrum with two maxima are due to the artifact connected with the use of a high concen- tration of the dye. It has been suggested that the cause of the low quantum yield of ThT aqueous and alcohol solutions is the breakage of the system of conjugated bonds due to the reorientation of the benzothiozole and benzaminic rings of ThT in the excited state with respect to one another. The main factor determining the high quantum yield of fluorescence of ThT incorporated in fibrils is the steric restriction of the rotation of the rings about one another under these conditions.
    [Show full text]
  • Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells
    14234 • The Journal of Neuroscience, October 21, 2015 • 35(42):14234–14250 Neurobiology of Disease Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells Marija Usenovic, Shahriar Niroomand, Robert E. Drolet, Lihang Yao, Renee C. Gaspar, Nathan G. Hatcher, Joel Schachter, John J. Renger, and Sophie Parmentier-Batteur Neuroscience, Merck Research Laboratories, West Point, Pennsylvania 19486 Neuronal inclusions of hyperphosphorylated and aggregated tau protein are a pathological hallmark of several neurodegenerative tauopathies, including Alzheimer’s disease (AD). The hypothesis of tau transmission in AD has emerged from histopathological studies of the spatial and temporal progression of tau pathology in postmortem patient brains. Increasing evidence in cellular and animal models supports the phenomenon of intercellular spreading of tau. However, the molecular and cellular mechanisms of pathogenic tau trans- mission remain unknown. The studies described herein investigate tau pathology propagation using human neurons derived from induced pluripotent stem cells. Neurons were seeded with full-length human tau monomers and oligomers and chronic effects on neuronal viability and function were examined over time. Tau oligomer-treated neurons exhibited an increase in aggregated and phos- phorylated pathological tau. These effects were associated with neurite retraction, loss of synapses, aberrant calcium homeostasis, and imbalanced neurotransmitter release. In contrast, tau monomer treatment did not produce any measureable changes. This work sup- ports the hypothesis that tau oligomers are toxic species that can drive the spread of tau pathology and neurodegeneration. Key words: Alzheimer’s disease; hiPSC neurons; neurodegeneration; pathology propagation; tau oligomer seeds Significance Statement Several independent studies have implicated tau protein as central to Alzheimer’s disease progression and cell-to-cell pathology propagation.
    [Show full text]
  • Advances in Development of Fluorescent Probes for Detecting Amyloid-Β Aggregates
    Acta Pharmacologica Sinica (2016) 37: 719–730 npg © 2016 CPS and SIMM All rights reserved 1671-4083/16 www.nature.com/aps Review Advances in development of fluorescent probes for detecting amyloid-β aggregates Ming-ming XU1, #, Wen-ming REN2, #, Xi-can TANG1, You-hong HU2, *, Hai-yan ZHANG1, * 1CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai 201203, China; 2State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China With accumulating evidence suggesting that amyloid-β (Aβ) deposition is a good diagnostic biomarker for Alzheimer’s disease (AD), the discovery of active Aβ probes has become an active area of research. Among the existing imaging methods, optical imaging targeting Aβ aggregates (fibrils or oligomers), especially using near-infrared (NIR) fluorescent probes, is increasingly recognized as a promising approach for the early diagnosis of AD due to its real time detection, low cost, lack of radioactive exposure and high-resolution. In the past decade, a variety of fluorescent probes have been developed and tested for efficiencyin vitro, and several probes have shown efficacy in AD transgenic mice. This review classifies these representative probes based on their chemical structures and functional modes (dominant solvent-dependent mode and a novel solvent-independent mode). Moreover, the pharmaceutical characteristics of these representative probes are summarized and discussed. This review provides important perspectives for the future development of novel NIR Aβ diagnostic probes. Keywords: Alzheimer’s disease; diagnostic biomarker; amyloid-β; optical imaging; near-infrared fluorescent probes Acta Pharmacologica Sinica (2016) 37: 719–730; doi: 10.1038/aps.2015.155; published online 21 Mar 2016 Introduction relief from symptoms.
    [Show full text]